Alnylam Pharmaceuticals Inc (ALNY)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$321.01

Buy

$337.86

arrow-up$0.83 (+0.26%)

Prices updated at 11 Apr 2026, 00:49 EDT

Prices minimum 15 mins delay

Prices in USD

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

NASDAQ

0.35%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2024	2025
	2,248m	3,714m
	1,925m	3,032m
	-177m	502m
	-7.87	13.51
	-278m	314m
	-179m	631m
Sales, General and administrative	976m	1,211m
Interest expenses	142m	253m
Provision for income taxes	-99m	9m
Operating expenses	2,102m	2,530m
Income before taxes	-377m	323m
Net income available to common shareholders	-278m	314m
	-2.18	2.39
Net interest income	-20m	-141m
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	-2.18	2.33
Free cash flow per share	0.1267	1.6658
Book value/share	0.2502	1.7669
Debt equity ratio	18.694282	1.562226

Balance sheet

Year chevron-l-regular chevron-r-regular	2024	2025
Current assets	3,295m	4,051m
Current liabilities	1,186m	1,466m
Total capital	1,092m	1,797m
Total debt	1,296m	1,278m
Total equity	67m	789m
Total non current liabilities	-	-
Loans	1,025m	1,008m
Total assets	4,240m	4,966m
Total liabilities	-	-
Cash and cash equivalents	966m	1,657m
Common stock	129m	132m

Cash flow

Year chevron-l-regular chevron-r-regular	2024	2025
Cash at beginning of period	815m	969m
Cash dividends paid	-	-
	-43m	465m
Investments (gains) losses	-117m	436m
	969m	1,659m
Net income	-	-
	-8m	524m
	-34m	-59m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.